Rapid Response in Migraine Patients Treated with Breath Powered (TM) Intranasal Delivery of Sumatriptan Powder (AVP-825): Efficacy Analysis by Prior Triptan History from the Phase 3 TARGET Study

Winner P.; Wallick C.; Shulman K. J.; Siegert S.; Yedigarova L.; Yonan C.

首页> 外文期刊>Headache >Rapid Response in Migraine Patients Treated with Breath Powered (TM) Intranasal Delivery of Sumatriptan Powder (AVP-825): Efficacy Analysis by Prior Triptan History from the Phase 3 TARGET Study

【24h】

Rapid Response in Migraine Patients Treated with Breath Powered (TM) Intranasal Delivery of Sumatriptan Powder (AVP-825): Efficacy Analysis by Prior Triptan History from the Phase 3 TARGET Study

机译：舒马曲坦粉末经呼吸动力（TM）鼻内给药治疗的偏头痛患者的快速反应（AVP-825）：根据三期TARGET研究的既往曲普坦病史进行疗效分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Headache》 |2015年第s3期|共2页
作者
Winner P.; Wallick C.; Shulman K. J.; Siegert S.; Yedigarova L.; Yonan C.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类诊断学;
关键词

相似文献

外文文献
中文文献
专利

1. Rapid Response in Migraine Patients Treated with Breath Powered (TM) Intranasal Delivery of Sumatriptan Powder (AVP-825): Efficacy Analysis by Prior Triptan History from the Phase 3 TARGET Study [J] . Winner P., Wallick C., Shulman K. J., Headache . 2015,第S3期

机译：舒马曲坦粉末经呼吸动力（TM）鼻内给药治疗的偏头痛患者的快速反应（AVP-825）：根据三期TARGET研究的既往曲普坦病史进行疗效分析
2. Breath Powered (TM) Nasal Delivery of Sumatriptan Powder (AVP-825): An Exploratory Analysis of Response in Migraine Patients Grouped by Baseline Headache Intensity from the Phase 3 TARGET Study [J] . Cady R. K., McAllister P., Spierings E. L., Headache . 2014,第S1期

机译：舒马普坦粉末（AVP-825）的呼吸动力（TM）鼻腔给药：对偏头痛患者的反应进行的探索性分析，该患者是根据第3阶段TARGET研究的基线头痛强度分组的
3. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered((R)) Exhalation Delivery System (Sumatriptan Nasal Powder) vs Oral Sumatriptan [J] . Silberstein Stephen, Winner Paul K., McAllister Peter J., Headache . 2017,第6期

机译：从随机罗盘研究的多次偏头痛攻击中的疗效和响应的效果和一致性的早期发病：AVP-825呼吸动力（（r））呼气输送系统（Sumatriptan鼻粉）与口腔舒适曲坦
4. AVP-825 Breath-Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks [O] . Stewart J Tepper, Roger K Cady, Stephen Silberstein, -1

机译：AVP-825呼吸动力鼻内给药系统包含22 mg舒马曲坦粉与100 mg mg舒马曲坦口服液用于急性偏头痛的治疗（COMPASS研究）：一项针对多种发作的随机比较临床试验
5. PND7 Total Migraine freedom for breath powered intranasal delivery of 22 mg Sumatriptan Powder (Avp-825) Versus 100 mg oral sumatriptan from the compass study of acute treatment of Migraine [O] . Halker R., Tepper S., Siegert S., 2015

机译：PND7从偏头痛急性治疗的指南针研究中得出的22毫克舒马曲坦散剂（Avp-825）与100毫克口服舒马曲坦鼻腔给药的总偏头痛总呼吸自由度

Rapid Response in Migraine Patients Treated with Breath Powered (TM) Intranasal Delivery of Sumatriptan Powder (AVP-825): Efficacy Analysis by Prior Triptan History from the Phase 3 TARGET Study

著录项

相似文献

相关主题

期刊订阅